Founded in Lexington, Kentucky, Hyku is a biotech company dedicated to revolutionizing drug discovery through precise covalent targeting of disease-causing proteins. The company's core mission is to improve patient lives by developing innovative medicines that address challenges such as selectivity, druggability, and resistance. Hyku's platform identifies molecules that covalently bind non-cysteine amino acids, enabling the creation of novel small molecule therapeutics aimed at various disease targets.

Hyku has attracted notable scientists and industry experts to its team, contributing to its rapid advancements in the field. The company has secured investments from leading biotech venture capital firms, underscoring its potential impact on the pharmaceutical industry. Key achievements include the successful identification of several promising therapeutic candidates, positioning Hyku as a significant player in the biotech sector. Through its pioneering approach, Hyku is poised to transform conventional treatment paradigms and make a lasting impact on patient care.